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Typically, patients with newly diagnosed type 2 diabetes (T2D) are initially encouraged to attempt to lower their blood glucose with nutrition and lifestyle management. As a result of the progressive pathophysiology of T2D, however, further treatment intensification will eventually be required. The next step usually involves addition of oral antidiabetic medications, often followed by exogenous insulin therapy. However, patients may resist treatment intensification, particularly when insulin is involved, because of concerns about hypoglycemia, body weight gain, and/or the complexity of such regimens. Incretin-based therapies such as dipeptidyl peptidase-4 inhibitors or glucagon-like peptide 1 (GLP-1) receptor agonists represent another option: these drugs carry a low risk of hypoglycemia and typically do not cause weight gain \[[@CR1], [@CR2]\].

IDegLira (Xultophy^®^, Novo Nordisk A/S, Bagsvaerd, Denmark) is a fixed-ratio combination of insulin degludec (IDeg; 100 U/mL) and liraglutide (Lira; 3.6 mg/mL). Insulin degludec is a basal insulin with an ultra-long duration of action and a flat pharmacodynamic profile \[[@CR3], [@CR4]\], and is associated with a lower risk of hypoglycemia than insulin glargine U100 \[[@CR5], [@CR6]\]. Liraglutide is a human GLP-1 analogue given once daily; it stimulates insulin secretion and lowers glucagon secretion in a glucose-dependent fashion, thus posing a low risk of hypoglycemia while helping to control both fasting and post-meal glucose levels \[[@CR7]\].

Liraglutide delays gastric emptying and reduces feelings of hunger. It is also used as a treatment for obesity, and therefore is often associated with weight loss in patients with diabetes \[[@CR8], [@CR9]\]. The pharmacokinetic properties of the two individual components, insulin degludec and liraglutide, are preserved in the fixed-ratio combination product IDegLira \[[@CR10]\]. IDegLira is administered in dose steps (1 U insulin degludec and 0.036 mg liraglutide) up to a maximum of 50 dose steps, corresponding to 50 U of insulin degludec and 1.8 mg of liraglutide.

The complementary mode of action of its two components means that IDegLira has the potential to be advantageous for patients with T2D who need to intensify therapy to achieve better glycemic control, but who may be reluctant to do so because of concerns about hypoglycemia, weight gain, and/or treatment complexity. In large, randomized, controlled, treat-to-target trials both in insulin-naïve \[[@CR11], [@CR12]\] and insulin-experienced patients \[[@CR13], [@CR14]\], IDegLira has been shown to improve glycemic control without increasing body weight or risk of hypoglycemia.

The beneficial effects shown in clinical trials, however, are achieved in cohorts with strictly defined inclusion and exclusion criteria, so it is also important to gauge how well IDegLira will perform in the more heterogeneous populations of patients encountered in real-world practice. Several reports indicate that, when used individually in real-world populations, insulin degludec \[[@CR15]--[@CR18]\] and liraglutide \[[@CR19], [@CR20]\] each retain the benefits demonstrated in prior randomized controlled trials. This study adds to the body of real-world data by describing outcomes in Swiss patients with a long duration of T2D who were empirically selected for treatment with IDegLira.

Methods {#Sec2}
=======

This was a prospective, open-label, single-center observational follow-up at the Cabinet Medical de Diabétologie in Lausanne, Switzerland, of all consecutive patients starting IDegLira between December 2014 and July 2015.

Patients began treatment with IDegLira for the following indications: not being well controlled under current treatment (HbA~1c~ greater than 8.0%), current treatment being too complicated for the patient (more than two oral antidiabetic medications and more than one injection daily), or it was believed the patient would benefit from the addition of the liraglutide component of IDegLira for weight management. No patients were excluded; however, it should be noted that in Switzerland, treatment with GLP-1 receptor agonists is reimbursed only for those patients whose body mass index (BMI) exceeds 28 kg/m^2^. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964, as revised in 2013 \[[@CR21]\]. Informed consent was obtained from all patients for being included in the study. The study was approved by the ethics committee for research in human beings in Lausanne, Switzerland.

IDegLira was initiated at 20 dose steps (20 U IDeg/0.72 mg liraglutide), except in insulin-naïve patients who began treatment at 16 dose steps. Thereafter, the dose was titrated in four dose steps once weekly, according to individualized fasting blood glucose targets. The individual HbA~1c~ target was set according to the European Association for the Study of Diabetes (EASD) recommendations. This value was converted to fasting plasma glucose for the patient. Patients were instructed to increase the dose of IDegLira by increments of four dose steps per week until achievement of the negotiated and individualized target.

For those patients requiring high doses of insulin (more than 50 units), a transition phase was included with addition of a slow-acting insulin during titration of IDegLira. If a patient reached the maximum of 50 dose steps and had still not reached good control, a second basal insulin was added (this was only necessary for one patient). Other concomitant therapies were allowed on the basis of physician and patient preference. At the time of switching treatment, each patient received a reminder on recommendations for following a balanced diet appropriate for type 2 diabetes, as well as encouragement to engage in at least 30 min of physical activity daily.

Information about glycemic control, total insulin dose, weight and blood pressure, as well as any adverse events, was collected from medical records and patient reports during clinic visits at baseline, at 3 months, and at the end of follow-up. Severe hypoglycemia was defined as events requiring the assistance of a third party.

Results {#Sec3}
=======

A total of 61 patients with T2D were followed up, with six (one male, five female) discontinuing treatment early because of adverse gastrointestinal events such as nausea and vomiting. Baseline demographics and prior diabetes treatment for all patients are shown in Table [1](#Tab1){ref-type="table"}. Almost all patients (*n* = 56, 91.8%) had been using insulin, and the population could be characterized as very overweight (mean BMI 34.3 kg/m^2^) and in poor glycemic control (mean HbA~1c~ 9.17%). Most patients continued with other concomitant therapy (sulfonylurea only: *n* = 1, 1.6%; metformin only: *n* = 36, 59.0%; metformin + sodium-glucose transporter-2 inhibitors: *n* = 9, 14.8%; metformin + sulfonylurea: *n* = 2, 3.3%; and metformin + basal insulin: *n* = 1, 1.6%). Twelve (19.7%) patients did not use any other therapy besides IDegLira for their diabetes.Table 1Baseline characteristics of 61 Swiss patients with type 2 diabetes who switched to IDegLiraCharacteristicValue^a^All patients\
*n* = 61Males\
*n* = 35Females\
*n* = 26Age (years)57.3 (range 25--80)Duration of diabetes (years)12.5 (range 1--31)11.514.2Weight (kg)96.5103.287.5BMI (kg/m^2^)34.333.934.9HbA~1c~ (%)9.29.09.4HbA~1c~ (mmol/mol)777579Systolic blood pressure (mmHg)146.4148.5142.5Diastolic blood pressure (mmHg)88.490.884.3Previous oral treatment (*n*, %)^b^ Metformin23 (37.7) Metformin + sitagliptin18 (29.5) Gliclazide12 (19.7) Liraglutide8 (13.1) Metformin + saxagliptin5 (8.2) Linagliptin3 (4.9) Other^c^10 (16.4)Previous insulin treatment (*n*, %) Insulin degludec30 (49.2) NPH9 (14.8) Insulin glargine5 (8.2) Insulin aspart/protamine crystallized insulin aspart4 (6.6) Insulin aspart/insulin degludec mix3 (4.9) Insulin detemir3 (4.9) Insulin lispro/insulin lispro protamine/NPH2 (3.3) None5 (8.2)*BMI* body mass index, *HbA* ~*1c*~ glycated hemoglobin, *IDegLira* insulin degludec/liraglutide, *NPH* neutral protamine Hagedorn^a^Values are means unless otherwise specified^b^Numbers add to \>100% owing to some patients being on multiple treatments^c^≤2 patients on any given medication

There were several clinically important benefits from switching to IDegLira for the 55 patients who completed 6 months of follow-up: mean HbA~1c~ improved (decrease of 1.7%) to 7.5% (Fig. [1](#Fig1){ref-type="fig"}a) and there was concomitant weight loss (Fig. [1](#Fig1){ref-type="fig"}b). Furthermore, switching to IDegLira resulted in a lower (−14.6 U) total insulin dose compared with baseline for those patients previously on insulin (Fig. [1](#Fig1){ref-type="fig"}c). Only one patient required a second basal insulin. A total of 20/61 (32.8%) of all patients and 20/55 (36.4%) of those who continued treatment required the maximum dose (50 dose steps) of IDegLira. There were small decreases in both mean systolic and mean diastolic blood pressure after treatment with IDegLira (Fig. [1](#Fig1){ref-type="fig"}d). When data from the six patients who did not complete follow-up were included in the calculation of baseline values, the decreases in HbA~1c~, insulin dose, and blood pressure did not change substantially. However, the magnitude of mean weight reduction achieved was lower (−0.4 kg). For the four non-completers for whom baseline weight was available, the mean value (77.5 kg) was much lower than for the group of completers (97.9 kg).Fig. 1Glucose control (**a**), body weight (**b**), insulin dose (**c**), and blood pressure (**d**) before and after switching to IDegLira in 55 Swiss patients who completed follow-up. *Red dotted line* in **a** shows normal value for HbA~1c~ (5.5%). *HbA* ~*1c*~ glycated hemoglobin, *IDegLira* insulin degludec/liraglutide, *Δ* mean change from baseline

There were no episodes of severe hypoglycemia during treatment with IDegLira in these Swiss patients.

Discussion {#Sec4}
==========

Before starting treatment with IDegLira, this real-world population of mostly insulin-experienced (91.9%) Swiss patients had a longer duration of diabetes (12.5 years), poorer glucose control (HbA~1c~ 9.2%), and greater mean body weight (96.5 kg) compared with patients enrolled in randomized trials of a comparable duration of follow-up (26--52 weeks) \[[@CR11], [@CR13], [@CR14]\].

As was reported in the randomized clinical trials of IDegLira, in this follow-up of Swiss patients with T2D of relatively long duration, mean HbA~1c~ decreased after approximately 26 weeks of treatment. The reduction in HbA~1c~ in these poorly controlled patients (−1.7%) was of a slightly lesser extent than those reported from the more restricted patient populations enrolled in randomized, treat-to-target trials (−1.8% to −1.9%) \[[@CR11], [@CR13], [@CR14]\]. Furthermore, the improvement in HbA~1c~ in the Swiss patients was detectable at approximately 12 weeks (Fig. [1](#Fig1){ref-type="fig"}a), which is consistent with data from randomized clinical trials \[[@CR22]\]. Unfortunately, as there were no observations in the period between switching to IDegLira and 12 weeks, it is not possible to determine precisely when the decrease began. These results are also consistent with a post hoc analysis of two randomized controlled trials, which showed that the reduction in HbA~1c~ was largely independent of disease duration or previous insulin dose \[[@CR23]\]. By comparison, the reduction in weight among those patients completing follow-up (−1.9 kg) in this study was greater than that reported in two randomized trials, −0.5 kg \[[@CR11]\] and −1.4 kg \[[@CR14]\], but less than that reported for another trial (−2.7 kg \[[@CR13]\]).

It should be mentioned that, very often, a seasonal weight variation is observed, with an increase during winter and a decrease during summer. Despite the fact that the 6-month observation period for these patients went from the beginning of winter to spring, there was a trend towards weight loss.

The decrease in systolic blood pressure in these patients (9.1 mmHg) is also consistent with results from randomized trials of liraglutide alone \[[@CR7]\] and IDegLira \[[@CR14]\].

The absence of any episodes of severe hypoglycemia is consistent with previously reported randomized trials of IDegLira in patients previously treated with insulin \[[@CR13], [@CR14]\]. In these larger-scale studies, only one episode of severe hypoglycemia was reported and this occurred during exercise (mountain climbing) and was resolved after consumption of a sweet beverage \[[@CR13]\].

Among the limitations of this study is the small sample size. This was fixed on the basis of the constraint of the observation period. For the chosen observation period, the number of patients included is representative of the volume of consultations performed by a private practice in a Swiss city. A longer period of observation would probably have better consolidated the data but it would have required a longer period and a greater workforce so as not to interfere with the usual functioning of the private practice. Data on adverse events such as hypoglycemia were not systematically solicited, nor were reported events assessed. Instead, they were recorded only if patients mentioned them during a follow-up visit. However, patients were generally very open about their experience with IDegLira during follow-up visits.

Patients initiated therapy at a higher dose of IDegLira (20 dose steps for insulin experienced, 16 dose steps for insulin naïve) than is recommended in the IDegLira prescribing information (16 dose steps for insulin experienced and 10 dose steps when transferring from oral therapy) \[[@CR24]\]. This shows how clinical practice in a real-world setting differs from clinical trials. In a clinical trial, where patients are monitored closely and regularly, titration can be slower, and frequent contact with participants can be helpful in ensuring treatment compliance. In real-life practice, where visits and follow-up are much less frequent, it may be necessary to be more aggressive in the titration process so that patients sense improvement and therefore retain the motivation to continue with treatment. The trade-off for starting with a higher dose of IDegLira, of course, may be in the inability of some patients to continue therapy because of gastrointestinal side effects. Given the lower body weight among patients who discontinued in this follow-up study, a more individualized titration schedule might be warranted, taking into account factors such as body weight. Despite the starting dose of IDegLira in this study being higher than that recommended, patients' total insulin requirements were nevertheless reduced from those at baseline over 6 months, with the achievement of an improved and acceptable mean HbA~1c~. Had a treat-to-target approach been used, it is likely that HbA~1c~ could have been further reduced.

Some aspects of diabetes treatment, which are just as important as glycemic control, have not been formally evaluated in this observational analysis, but deserve to be mentioned here. According to patients' feedback, the process of changing treatment to IDegLira was itself helpful by increasing their motivation to better manage their diabetes. Examples include being more careful about what they eat and when, and engaging in more frequent self-measured blood glucose testing. This in turn has an impact on improving glycemia. For some patients, concurrent stressful life events (e.g., serious illness in a spouse, divorce) may have interfered with optimal diabetes management. In others, while switching treatment did not immediately result in improvements in glycemic control, there were nevertheless important benefits with respect to quality of life (e.g., being able to engage in more regular exercise owing to feeling less sick).

Conclusion {#Sec5}
==========

Switching to IDegLira, mostly from regimens of other insulin treatments in conjunction with oral antidiabetic medications in a real-world population in patients treated for T2D, resulted in improved glucose control with a lower insulin dose and without weight gain.
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